HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
COVID-19 Drug Development
COVID-19 drug development is a research process to discover a preventative and therapeutic prescription of drugs that would control the severity of coronavirus disease. From 2020 to 2021, various drug companies, biotechnology firms, university research groups, and health organizations were started developing over 600 potential therapies for corona virus disease with various stages of preclinical or clinical research, with 391 therapeutic candidates in clinical trials, as of January 2021.
Committee Members
Miroslav Radenkovic
University of Belgrade, Serbia
A C Matin
Stanford University, United States
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Consolato M Sergi
University of Ottawa, Canada PDDS 2024 Speakers
Miroslav Radenkovic
University of Belgrade, Serbia
A C Matin
Stanford University, United States
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Andreas M Papas
Antares Health Products, United States
Consolato M Sergi
University of Ottawa, Canada
Thomas Ullrich
Novartis Biomedical Research, SwitzerlandSubmit your abstract Today
Title : Nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects
A C Matin, Stanford University, United States
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Clinical decision making in advanced and metastatic breast cancer cases between PARP inhibitors and CDK4/6 inhibitors
Priya Hays, Hays Documentation Specialists, LLC, United States
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Novel nano drug platform for pharmacologically inducing therapeutic hypothermia (TH) after traumatic brain injury (TBI)
Jorge David Tovar Castro, University of Miami Miller School of Medicine, United States
Title : Global drug development - Trends, challenges and opportunities
Gurpreet Singh, IQVIA, United Kingdom
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland
Title : Synthesis and properties of new unique heterocyclic systems: Pyrido[3'',2'':4',5']furo(thieno)[3',2':4,5]pyrimido[2,1-f][1,2,4]triazines
Anush, National Academy of Sciences of the Republic of Armenia, Armenia
Title : Development and evaluation of prolonged-release dutasteride transdermal delivery system
Shereen M. Assaf, Jordan University of Science and Technology, Jordan